BAJAJ BROKING

Notification
No new Notification messages
Anya Polytech & Fertilizers IPO is Open!
Apply for the Anya Polytech & Fertilizers IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

Mankind Pharma Signs Licensing Pact with Innovent for Sintilimab

Listen to our Podcast: Grow your wealth and keep it secure.

0:00 / 0:00

Synopsis:

Mankind Pharma signed a licensing deal with Innovent Biologics to introduce Sintilimab, an anti-cancer PD-1 immunotherapy, in India. Estimated market size is ₹8,000 crore. Mankind Pharma share price remains stable amid this expansion into oncology.

Mankind Pharma news today

Mankind Pharma has announced a licensing agreement with Chinese pharmaceutical giant Innovent Biologics to introduce Sintilimab, a cutting-edge PD-1 immunotherapy, in India. The partnership grants Mankind exclusive rights to register, import, market, sell, and distribute the drug, while Innovent oversees manufacturing and supply. This development signifies Mankind’s strategic focus on strengthening its oncology portfolio in the ₹8,000-crore Indian oncology market.

Also read: Jubilant FoodWorks Partners with Coca-Cola for Beverage Supply

MANKIND PHARMA LIMITED

Trade

2871.75-44.89 (-1.53 %)

Updated - 27 December 2024
2943.95day high
DAY HIGH
2865.10day low
DAY LOW
246296
VOLUME (BSE)

Key Takeaways

  • Drug Name: Sintilimab (Marketed as TYVYT in China).

  • Mechanism: Blocks PD-1/PD-L1 pathway to enhance T-cell activity against cancer cells.

  • Launch Timeline: Expected in three years post Phase III trials and regulatory approvals.

  • Market Size: Indian oncology market valued at ₹8,000 crore.

  • Mankind Pharma Share Price: Stable amid announcement.

Also read: IndusInd Bank to Sell ₹1,573-Crore MFI Retail Loan Pool in Auction

Sintilimab Overview

Sintilimab, developed by Innovent Biologics in collaboration with Eli Lilly, is a monoclonal antibody targeting multiple cancer types. It is approved for eight indications in China, including:

Cancer Type

Indications

Non-Small Cell Lung Cancer

First-Line Treatment

Liver Cancer

Advanced Stages

Gastric Cancer

First-Line Therapy

Esophageal Cancer

Recurrence or Advanced Cases

Endometrial Cancer

Advanced Stages

Hodgkin’s Lymphoma

Second-Line Therapy

Strategic Importance for Mankind Pharma

Mankind’s entry into oncology began in 2023 with the acquisition of Panacea Biotec for ₹1,872 crore. The addition of Sintilimab aligns with the company's focus on biologics and immunotherapies as future cancer treatments. The drug's competitive pricing is expected to enhance accessibility in the Indian market.

Mankind Pharma Share Price and Market Impact

Mankind Pharma share price remains steady following the announcement, reflecting investor confidence in its strategic expansion. With over 16,000 personnel and 13,000 stockists, Mankind’s robust distribution network is well-positioned to support the launch. 

Mankind Pharma’s licensing agreement with Innovent Biologics marks a significant step towards transforming cancer care in India. By introducing Sintilimab, the company is poised to make advanced immunotherapy accessible to Indian patients while solidifying its position in the oncology market.

Also read: Gensol Engineering Secures ₹897-Crore Contract for NTPC REL Solar Projects

Do you have a trading account app or demat account app?

You can open an account with Bajaj Broking in minutes.

Download the Bajaj Broking app now from Play Store or App Store.

Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.

This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

For All Disclaimers Click Here: https://bit.ly/3Tcsfuc

Share this article: 

Read More Blogs

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

8 Lacs+ Users

icon-with-text

4.4+ App Rating

icon-with-text

4 Languages

icon-with-text

₹4700+ Cr MTF Book

icon-with-text